In the BioHarmony Drug Report Database

"Preview" Icon

Eltrombopag olamine

Promacta, Revolade (eltrombopag olamine) is a small molecule pharmaceutical. Eltrombopag olamine was first approved as Promacta on 2008-11-20. It is used to treat aplastic anemia and thrombocytopenic purpura idiopathic in the USA. It has been approved in Europe to treat thrombocytopenic purpura idiopathic. Promacta’s patents are valid until 2027-08-01 (FDA).

 

Trade Name

 

Revolade
 

Common Name

 

eltrombopag olamine
 

ChEMBL ID

 

CHEMBL461806
 

Indication

 

aplastic anemia, thrombocytopenic purpura idiopathic
 

Drug Class

 

Image (chem structure or protein)

Eltrombopag olamine structure rendering